Tell us about your top U.S. Supreme Court or federal appeals court victory over the past year and how you and your team achieved the win.

[The U.S. Court of Appeals for] the Federal Circuit unanimously affirmed our posttrial success vacating a $200 million jury verdict against our client Gilead Sciences in a patent infringement case with Merck involving Gilead’s blockbuster Sovaldi and Harvoni hepatitis C drugs. After a jury awarded Merck $200 million in damages, amounting to one-tenth of Merck’s $2 billion claim, the district court erased the verdict, finding Merck had forfeited its right to assert its patents against Gilead because of litigation and business misconduct constituting unclean hands. Our strong writ[ing] and oral advocacy convinced the Federal Circuit to affirm both that result and the $14 million legal fee award to Gilead. The Supreme [Court] denied certiorari.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]